Strategic Opportunity High-value medical device candidate for strategic partnerships with cardiology and peripheral vascular interventions, focusing on SirPlux Duo’s dual-drug delivery capability to address restenosis and small-vessel disease.

Clinical Readiness Clinical-stage positioning with FDA Breakthrough Designation supports collaboration with hospital systems and contract development/manufacturing organizations seeking early access programs and pivotal trial support.

Funding Momentum Recent oversubscribed Series B funding signals investor confidence and a window for co-development deals, licensing agreements, and co-investment opportunities to accelerate commercialization.

Licensing Advantage Exclusive license from Cleveland Clinic combined with biodegradable nanoparticle platform creates a defensible tech moat; target large medtech distributors and vascular surgery franchises seeking differentiated DCB solutions.

Market Readiness Revenue and growth potential aligned with cardiovascular and peripheral artery disease trends; pursue pilot deployments, site-level trials, and payer-ready value propositions emphasizing reduced retreatment and tissue retention benefits.